Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to be Presented by Precision Therapeutics, Inc. at WAGO Annual Meeting
5/6/2013 7:11:39 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that compelling results from a clinical study which demonstrates whether ChemoFx® is an independent predictive factor for progression free survival and overall survival in recurrent ovarian cancer will be presented at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists (WAGO). The meeting will be held from June 27-29, 2013 at the W Seattle in Seattle, Washington.
Help employers find you! Check out all the jobs and post your resume.
comments powered by